Hope Rugo, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss data from CAPItello-291 on capivasertib and how it has changed the treatment landscape in HR+ breast cancer.
EP. 1: Rationale and Study Design of CAPItello-291 in HR+ Advanced Breast Cancer
Hope Rugo, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the rationale and study design for CAPItello-291 in HR+ advanced breast cancer.
Watch
EP. 2: Biomarker Testing and Prevalence of AKT1/PIK3CA/PTEN Mutations in Breast Cancer
Medical oncologists provide insights on biomarker testing and the prevalence of AKT1, PIK3CA, and PTEN mutations in breast cancer.
EP. 3: Key Data from CAPItello-291 in HR+ Breast Cancer
Hope Rugo, MD, reviews key data from CAPItello-291 on capivasertib in patients with HR+ breast cancer, highlighting progression-free survival and overall survival.
EP. 4: Adverse Event Data from CAPItello-291 in HR+ Breast Cancer
Focusing on the safety profile, the Oncology Brothers and Hope Rugo, MD, review safety data from CAPItello-291 and discuss adverse event management practices for patients with breast cancer.
EP. 5: Key Takeaways from CAPItello-291 in HR+ Breast Cancer
Following a comprehensive review of CAPItello-291, Rohit Gosain, MD, and Rahul Gosain, MD, provide closing thoughts on key takeaways.